AKAP11 Antibody

What is AKAP11 and what cellular functions does it regulate?

AKAP11, also known as AKAP220, KIAA0629, and PRKA11, belongs to the AKAP110 family and functions as an A-kinase anchoring protein that binds to regulatory subunits of protein kinase A (PKA), anchoring them to specific subcellular compartments . The protein has a calculated molecular weight of 211 kDa but is typically observed at approximately 220 kDa in experimental systems . AKAP11 is expressed at high levels throughout spermatogenesis and in mature sperm, binding both RI and RII subunits of PKA in testis . Beyond reproductive tissues, AKAP11 serves critical functions in cell cycle control of both somatic cells and germ cells . Recent research has identified AKAP11 as an autophagy receptor that contains a conserved LC3-interacting region (LIR) WSNL at its C-terminal domain, mediating selective autophagy and PKA activation that fuels mitochondrial metabolism during glucose starvation .

What are the optimal applications for AKAP11 antibodies?

AKAP11 antibodies have been validated for multiple experimental applications with varying degrees of optimization:

For Western blot applications, AKAP11 antibodies detect a band at approximately 220 kDa, consistent with the observed molecular weight of the protein . When using AKAP11 antibodies for immunohistochemistry, optimal results are achieved with paraffin-embedded tissue sections at dilutions between 1:20 and 1:200, as validated in human kidney and brain tissues .

What are the recommended storage conditions for maintaining AKAP11 antibody activity?

To maintain optimal activity of AKAP11 antibodies, adhere to the following storage guidelines:

These storage conditions minimize freeze-thaw cycles and protein denaturation, preserving antibody functionality for downstream applications.

How can I validate the specificity of an AKAP11 antibody for my research?

Validating AKAP11 antibody specificity requires a multi-faceted approach:

• Positive controls: Use tissues known to express AKAP11, such as human placenta, kidney, or brain tissues, which have been validated in previous studies .

• CRISPR-Cas9 knockout validation: Generate AKAP11 knockout cell lines (as described in research using HEK293T and HeLa cells) to confirm antibody specificity through loss of signal in knockout samples .

• siRNA knockdown: Perform transient knockdown of AKAP11 using targeted siRNAs and confirm reduction in antibody signal proportional to knockdown efficiency.

• Recombinant protein detection: Test the antibody against recombinant AKAP11 protein fragments (such as those used for immunization) to verify binding to the target epitope .

• Cross-reactivity assessment: Evaluate potential cross-reactivity with other AKAP family members, particularly those with high sequence homology.

For advanced validation, co-immunoprecipitation experiments paired with mass spectrometry can identify antibody-bound proteins to confirm specificity for AKAP11.

What experimental approaches are most effective for studying AKAP11's role in autophagy?

To investigate AKAP11's function as an autophagy receptor, consider these methodological approaches:

• Autophagosome formation analysis: Use GFP-LC3B stable cell lines to visualize autophagosome formation and colocalization with AKAP11 during nutrient starvation, as demonstrated in HEK293T cells .

• LC3 interaction studies: Employ GST pull-down assays with GST-tagged LC3A, LC3B, or GABARAP fusion proteins incubated with cell lysates expressing HA-tagged AKAP11 to characterize protein-protein interactions .

• LIR motif mutagenesis: Generate AKAP11 constructs with mutations in the conserved LC3-interacting region (WSNL to AAAA) to examine the functional significance of this domain in autophagy .

• Co-immunoprecipitation assays: Analyze interactions between AKAP11, LC3, and RIα through co-IP experiments under different nutritional conditions (normal vs. starvation) .

• Autophagic flux measurement: Use bafilomycin A1 treatment in combination with nutrient starvation to differentiate between effects on autophagosome formation versus degradation.

These approaches can be complemented with live-cell imaging to track the dynamics of AKAP11-mediated autophagy in real-time.

How can I optimize Western blot protocols for detecting AKAP11?

Optimizing Western blot protocols for AKAP11 detection requires special considerations due to its high molecular weight (220 kDa):

• Gel preparation: Use low percentage (6-8%) polyacrylamide gels to allow proper resolution of high molecular weight proteins. Consider gradient gels (4-15%) for simultaneous detection of AKAP11 and lower molecular weight interacting partners.

• Transfer conditions: Employ wet transfer methods with prolonged transfer times (3-4 hours or overnight) at low voltage (30V) and cold conditions to ensure complete transfer of high molecular weight proteins.

• Blocking optimization: Use 5% non-fat dry milk in TBST for general blocking, but consider 5% BSA if high background is observed.

• Antibody dilution and incubation: For primary antibody, use recommended dilutions between 1:200-1:1000 in blocking buffer and incubate overnight at 4°C with gentle rocking to maximize specific binding.

• Positive control selection: Include human placenta tissue lysate as a positive control, which has been validated for AKAP11 expression .

• Signal enhancement: For weak signals, consider using enhanced chemiluminescence (ECL) substrates specifically designed for high-sensitivity detection.

• Stripping and reprobing: When analyzing multiple proteins, use mild stripping buffers to avoid epitope damage if reprobing for AKAP11.

What are the key considerations when using immunohistochemistry to detect AKAP11 in tissue samples?

For optimal immunohistochemical detection of AKAP11 in tissue samples:

• Tissue processing: Use 10% neutral buffered formalin fixation followed by paraffin embedding, as this has been validated for AKAP11 antibody reactivity in human kidney and brain tissues .

• Antigen retrieval: Perform heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) to unmask epitopes that may be cross-linked during fixation.

• Antibody dilution: Start with a dilution range of 1:20-1:200 as recommended , optimizing based on signal-to-noise ratio in your specific tissue samples.

• Incubation conditions: Incubate primary antibody overnight at 4°C in a humidified chamber to enhance specific binding while minimizing background.

• Detection system selection: Use a sensitive detection system such as polymer-based HRP detection for optimal visualization of AKAP11 localization.

• Positive control tissues: Include human kidney tissue sections as positive controls, which have been validated for AKAP11 expression .

• Counterstaining: Use hematoxylin counterstaining at optimized timing to provide cellular context without obscuring AKAP11-specific signals.

• Multi-labeling strategies: Consider fluorescent detection methods for co-localization studies with other proteins in the PKA pathway or autophagy machinery.

How can I investigate AKAP11's role in PKA signaling during glucose starvation?

To study AKAP11's function in PKA activation during metabolic stress:

• FRET-based PKA activity monitoring: Utilize fluorescence resonance energy transfer (FRET)-based biosensors to measure PKA activity in live cells upon glucose starvation, comparing wild-type and AKAP11 knockout or knockdown cells .

• Phospho-CREB analysis: Measure phosphorylation levels of CREB (cAMP response element-binding protein), a downstream target of PKA, using phospho-specific antibodies in Western blot to assess PKA activity .

• RIα degradation kinetics: Monitor the degradation of RIα in response to starvation conditions in the presence or absence of AKAP11 to establish the relationship between autophagy-mediated RIα degradation and PKA activation .

• Mitochondrial metabolism assessment: Evaluate mitochondrial function parameters (oxygen consumption rate, ATP production) in wild-type versus AKAP11-deficient cells under glucose starvation to connect PKA activation to metabolic outcomes .

• Cell survival assays: Conduct viability assays under glucose deprivation conditions to correlate AKAP11-mediated PKA activation with cell survival phenotypes.

• Rescue experiments: Perform complementation studies with wild-type AKAP11 or LIR-mutant AKAP11 in knockout cells to establish the causal relationship between AKAP11's autophagy receptor function and PKA activation.

What techniques are most effective for studying the interaction between AKAP11 and LC3?

To characterize the interaction between AKAP11 and LC3 proteins:

• GST pull-down assays: Purify GST-tagged LC3A, LC3B, or GABARAP fusion proteins and incubate with cell lysates expressing HA-tagged AKAP11, followed by pull-down with GST beads to assess direct binding .

• Co-immunoprecipitation: Utilize cells stably expressing GFP-LC3B to co-immunoprecipitate endogenous AKAP11, or conversely, immunoprecipitate HA-tagged AKAP11 to detect interaction with LC3 proteins .

• Mutation analysis: Generate AKAP11 constructs with mutations in the LC3-interacting region (LIR) motif (WSNL to AAAA) to determine the specificity of the interaction through comparative binding assays .

• Fluorescence microscopy: Perform confocal microscopy to visualize colocalization of AKAP11 with LC3-positive autophagosomal structures, particularly under starvation conditions .

• Proximity ligation assay (PLA): Use PLA to detect and quantify AKAP11-LC3 interactions in situ with high sensitivity and spatial resolution.

• Structural analysis: Consider computational modeling or structural biology approaches (X-ray crystallography, cryo-EM) to characterize the molecular details of the AKAP11-LC3 interaction interface.

How can I differentiate between AKAP11 and other AKAP family members in my experiments?

Distinguishing AKAP11 from other AKAP family members requires careful experimental design:

• Antibody selection: Choose antibodies raised against unique epitopes of AKAP11 rather than conserved domains shared among AKAP family members. Verify specificity through testing in AKAP11 knockout systems .

• qRT-PCR primer design: Design primers targeting unique regions of AKAP11 mRNA sequence for specific quantification of gene expression, validating amplification specificity through sequencing or melt curve analysis.

• siRNA/shRNA specificity validation: When performing knockdown experiments, validate the specificity of targeting sequences by confirming selective reduction of AKAP11 without affecting other AKAP family members.

• Domain-specific functional analysis: Focus on unique structural features of AKAP11, such as its specific LC3-interacting region (LIR) WSNL at the C-terminal domain, which may not be conserved in other AKAP proteins .

• Interactome characterization: Identify AKAP11-specific binding partners (e.g., RIα in the context of autophagy) that distinguish its function from other AKAP family members.

• Expression pattern analysis: Utilize tissue or cell-type specific expression patterns to discriminate AKAP11 function in contexts where other AKAPs may have minimal expression.

What are common challenges when working with AKAP11 antibodies and how can they be addressed?

Researchers frequently encounter these challenges when working with AKAP11 antibodies:

• High molecular weight detection issues:

  • Challenge: Incomplete transfer of 220 kDa AKAP11 protein in Western blots

  • Solution: Use low percentage gels (6-8%), extend transfer time, and employ wet transfer methods at low voltage

• Non-specific binding:

  • Challenge: Multiple bands observed in Western blot

  • Solution: Increase antibody dilution (1:500-1:1000), optimize blocking conditions, and validate with AKAP11 knockout controls

• Weak signal intensity:

  • Challenge: Low detection sensitivity in tissues with moderate AKAP11 expression

  • Solution: Implement signal amplification methods, extend primary antibody incubation (overnight at 4°C), and use high-sensitivity detection reagents

• Epitope masking in fixed tissues:

  • Challenge: Poor immunohistochemical staining despite confirmed expression

  • Solution: Optimize antigen retrieval methods, testing both citrate and EDTA-based buffers at various pH levels and treatment durations

• Antibody batch variation:

  • Challenge: Inconsistent results between antibody lots

  • Solution: Validate each new lot against previous standards and consider procuring larger quantities of validated lots for long-term studies

• Cross-reactivity with related proteins:

  • Challenge: Difficulty distinguishing between AKAP family members

  • Solution: Confirm specificity using knockout/knockdown controls and peptide competition assays with the immunizing peptide

How can I validate results from AKAP11 knockout or knockdown experiments?

To ensure robust interpretation of AKAP11 loss-of-function studies:

• Multiple knockout/knockdown strategies: Generate AKAP11-deficient models using different approaches (CRISPR-Cas9 with multiple guide RNAs, shRNA, siRNA) to control for potential off-target effects .

• Rescue experiments: Reintroduce wild-type AKAP11 expression in knockout cells to confirm phenotype reversal, establishing causality between AKAP11 loss and observed effects .

• Protein level verification: Confirm complete protein elimination in knockout models or quantify knockdown efficiency through Western blot, with careful attention to potential truncated proteins or splice variants.

• Transcript analysis: Perform RT-PCR and sequencing to verify the genetic modification at the mRNA level, particularly for CRISPR-edited cell lines.

• Off-target effect assessment: Use computational prediction tools to identify potential off-target sites for CRISPR guide RNAs, followed by targeted sequencing of these regions.

• Functional readouts: Measure established AKAP11-dependent processes, such as PKA activation during glucose starvation or RIα autophagy-mediated degradation, as functional validation of the knockout .

• Clonal variation control: When using single-cell derived knockout clones, analyze multiple independent clones to control for clonal variation unrelated to AKAP11 deficiency.

What are the critical factors in reproducing published AKAP11 research findings?

To successfully reproduce published findings related to AKAP11:

• Cell line authentication: Verify the identity of cell lines through STR profiling, as cellular context significantly impacts AKAP11 function and regulation.

• Culture conditions standardization: Maintain consistent culture conditions, particularly regarding cell density, passage number, and serum batch, which can affect basal autophagy levels and PKA signaling.

• Starvation protocol details: For experiments involving nutrient deprivation, strictly adhere to published protocols regarding starvation medium composition (e.g., EBSS), duration, and cell density during treatment .

• Antibody selection and validation: Use antibodies targeting the same epitopes as in published work, validating their specificity in your experimental system.

• Quantification methods: Employ the same quantification approaches used in the original publications, particularly for parameters like PKA activity or autophagy flux.

• Experimental timing: Pay careful attention to the timing of interventions and measurements, especially for dynamic processes like autophagy and PKA signaling.

• Statistical analysis: Apply the same statistical tests and sample sizes as in the original studies to ensure comparable power and interpretation.

• Reagent sources: When possible, obtain critical reagents (plasmids, cell lines) directly from the original authors to minimize variation introduced by reagent recreation.

What emerging technologies can advance our understanding of AKAP11 biology?

Several cutting-edge technologies hold promise for deepening our understanding of AKAP11 function:

• Proximity labeling proteomics (BioID, APEX): These approaches can map the dynamic AKAP11 interactome under different cellular conditions, revealing context-specific protein interactions beyond currently known partners like LC3 and PKA regulatory subunits.

• CRISPR activation/inhibition screens: CRISPRa/CRISPRi approaches can identify genes that modulate AKAP11-dependent functions, potentially revealing new regulatory pathways.

• Live-cell super-resolution microscopy: Techniques like STORM or PALM can visualize AKAP11's subcellular localization and dynamics with nanometer precision, particularly during autophagosome formation.

• Single-cell multi-omics: Combining single-cell transcriptomics, proteomics, and metabolomics can reveal cell-to-cell variability in AKAP11 expression and function across different tissues and disease states.

• Cryo-electron microscopy: Structural determination of AKAP11 complexes with PKA and autophagy machinery components could provide mechanistic insights into how these interactions are regulated.

• Optogenetic approaches: Light-controlled activation or inhibition of AKAP11 function could enable temporal precision in studying its roles in PKA signaling and autophagy.

• Patient-derived organoids: These systems could translate AKAP11 research findings into physiologically relevant human tissue contexts, particularly for tissues known to express AKAP11.

How might AKAP11 dysfunction contribute to human diseases?

Based on current understanding of AKAP11 functions, several disease connections warrant investigation:

• Cancer metabolism: AKAP11's role in PKA activation during glucose starvation suggests potential involvement in tumor cell adaptation to nutrient-poor microenvironments . Research should examine AKAP11 expression and function in various cancer types, particularly those characterized by metabolic reprogramming.

• Neurodegenerative disorders: Given AKAP11's function in autophagy and its expression in brain tissue , dysfunction might contribute to protein aggregation diseases where autophagy plays a protective role, such as Alzheimer's or Parkinson's disease.

• Male infertility: AKAP11's high expression throughout spermatogenesis and in mature sperm suggests that mutations or dysfunction could impact male reproductive health through altered PKA signaling in reproductive tissues.

• Metabolic disorders: As a regulator of cellular responses to glucose deprivation , AKAP11 variants might influence susceptibility to diabetes or other metabolic diseases through effects on energy homeostasis.

• Autophagy-related diseases: Conditions characterized by autophagy dysregulation might involve AKAP11 dysfunction, given its role as an autophagy receptor mediating selective degradation of RIα .

Systematic analyses of AKAP11 genetic variants in patient cohorts, combined with functional studies in disease models, could establish causal relationships between AKAP11 dysfunction and specific pathologies.